InvestorsHub Logo
Followers 57
Posts 5696
Boards Moderated 0
Alias Born 12/13/2004

Re: dia76ca post# 2371

Tuesday, 09/12/2017 9:50:23 PM

Tuesday, September 12, 2017 9:50:23 PM

Post# of 6032
The FDA is under a lot of pressure to reduce drug costs. Clearly Heat is having great success in their Phase II NSCLC trial combining HS-110 with Opdivo. If they can safely double or triple Opdivo`s efficacy with a drug that will only cost $1,000 or less...the FDA should be listening.

The FDA can also reduce drug costs by speeding up drug approvals. HS-110 has an outstanding safety profile and should be an exemplary candidate for an accelerated approval.

And once one of The ImPACT and ComPACT family of drugs are approved subsequent approvals should come rapidly...as they have for other drugs. Things are looking very good. I look forward to hearing more about the Type C meeting with the FDA!

"The refusal of the real is the number one dogma of our time" Rene Girard

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NHWK News